Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. 2008

Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan.

BACKGROUND The effect of dual infection with herpes simplex virus type 1 (HSV-1) mutants on human oral squamous cell carcinoma (SCC) cells was examined. METHODS Human oral SCC cells were infected with gamma1(34.5) gene-deficient HSV-1 R849 and HSV-1 HF that has multiple mutations and induces cell fusion. Cell viability was measured by LDH release assay. Athymic mice were injected with oral SCC cells into the buccal region to induce subcutaneous tumors. RESULTS Oral SCC cells were infected with R849, followed by infection with R849 or HF. Virus production was elevated by both strains of HSV-1. Although the release of LDH from R849-infected cells was increased by secondary infection with R849 or HF, the effect of HF was more remarkable. When nude mouse tumors were treated with R849, HF, R849+R849, or R849+HF, treatment with R849+HF was the most effective. CONCLUSIONS These results suggest that fusion-inducing virus HF enhances the oncolytic ability of gamma1(34.5) gene-deficient HSV-1 and provides a rationale for using fusogenic viruses as enhancing agents

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050130 Oncolytic Virotherapy Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells. Oncolytic Virus Therapy,Virotherapy, Oncolytic,Oncolytic Virotherapies,Oncolytic Virus Therapies,Therapies, Oncolytic Virus,Therapy, Oncolytic Virus,Virotherapies, Oncolytic,Virus Therapies, Oncolytic,Virus Therapy, Oncolytic
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
May 2017, The Japanese dental science review,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
December 2002, Cancer gene therapy,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
August 2008, Head & neck,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
December 2009, Oral oncology,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
April 2013, The Journal of general virology,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
June 2008, Journal of dermatological science,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
January 2015, Oncolytic virotherapy,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
March 2009, Cancer gene therapy,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
April 2016, Cancer gene therapy,
Fumi Ogawa, and Hiroo Takaoka, and Soichi Iwai, and Keiko Aota, and Yoshiaki Yura
January 2018, Cancers,
Copied contents to your clipboard!